KR20240119118A - 알파-l-이두 로니다제 효소를 포함하는 융합 단백질 및 이의 방법 - Google Patents

알파-l-이두 로니다제 효소를 포함하는 융합 단백질 및 이의 방법 Download PDF

Info

Publication number
KR20240119118A
KR20240119118A KR1020247022697A KR20247022697A KR20240119118A KR 20240119118 A KR20240119118 A KR 20240119118A KR 1020247022697 A KR1020247022697 A KR 1020247022697A KR 20247022697 A KR20247022697 A KR 20247022697A KR 20240119118 A KR20240119118 A KR 20240119118A
Authority
KR
South Korea
Prior art keywords
polypeptide
amino acid
acid sequence
idua
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022697A
Other languages
English (en)
Korean (ko)
Inventor
고우리수드하 아두수밀리
올리버 브레이어 데이비스
미할리스 에스. 카리올리스
카탈 에스. 마혼
슈리슈티 티야기
켄스케 야마노쿠치
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Publication of KR20240119118A publication Critical patent/KR20240119118A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247022697A 2021-12-17 2022-12-16 알파-l-이두 로니다제 효소를 포함하는 융합 단백질 및 이의 방법 Pending KR20240119118A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291283P 2021-12-17 2021-12-17
US63/291,283 2021-12-17
PCT/US2022/053196 WO2023114485A1 (en) 2021-12-17 2022-12-16 Fusion proteins comprising alpha-l-iduronidase enzymes and methods

Publications (1)

Publication Number Publication Date
KR20240119118A true KR20240119118A (ko) 2024-08-06

Family

ID=85175822

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022697A Pending KR20240119118A (ko) 2021-12-17 2022-12-16 알파-l-이두 로니다제 효소를 포함하는 융합 단백질 및 이의 방법

Country Status (12)

Country Link
US (1) US20250136963A1 (https=)
EP (1) EP4448746A1 (https=)
JP (1) JP2024546129A (https=)
KR (1) KR20240119118A (https=)
CN (1) CN118401660A (https=)
AR (1) AR128003A1 (https=)
AU (1) AU2022415476A1 (https=)
CA (1) CA3241240A1 (https=)
IL (1) IL313553A (https=)
MX (1) MX2024007319A (https=)
TW (1) TW202340459A (https=)
WO (1) WO2023114485A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218000A2 (en) * 2014-11-10 2017-09-20 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models
AU2018345303B2 (en) 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CA3101202A1 (en) * 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
EP4100419A4 (en) * 2020-02-07 2024-05-29 Denali Therapeutics Inc. METHODS OF TREATING HUNTER SYNDROME

Also Published As

Publication number Publication date
WO2023114485A1 (en) 2023-06-22
AU2022415476A1 (en) 2024-07-04
JP2024546129A (ja) 2024-12-17
CN118401660A (zh) 2024-07-26
IL313553A (en) 2024-08-01
MX2024007319A (es) 2024-07-22
CA3241240A1 (en) 2023-06-22
US20250136963A1 (en) 2025-05-01
EP4448746A1 (en) 2024-10-23
AR128003A1 (es) 2024-03-20
TW202340459A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
JP2023123757A (ja) トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
US11884944B2 (en) Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
JP2023179600A (ja) 酵素補充療法用酵素を含む融合タンパク質
CN113785054A (zh) 包含艾杜糖醛酸2-硫酸酯酶的蛋白质分子制剂
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
US20240148866A1 (en) Anti-transferrin receptor fusion proteins and methods of use thereof
US20250136963A1 (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
US12378540B1 (en) Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
WO2024206161A1 (en) Abeta-targeting proteins and methods of use
HK40114509A (zh) 包含α-L-艾杜糖醛酸酶的融合蛋白和方法
EA051395B1 (ru) Слитые белки, содержащие ферменты сульфоглюкозамин-гидролазы, и связанные с ними способы
WO2026006173A1 (en) Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof
HK40103089A (zh) 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
WO2024220986A2 (en) Methods of increasing sialic acid levels in recombinant glycosylated proteins
EP4634218A2 (en) Methods and compositions related to engineered transferrin receptor-binding molecules
HK40064377A (en) Formulations of protein molecules comprising iduronate 2-sulfatase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000